Published in J Biol Inorg Chem on March 11, 2010
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. Nat Commun (2014) 1.00
X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). J Med Chem (2013) 0.88
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. J Inorg Biochem (2012) 0.86
Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles. Inorg Chem (2013) 0.85
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer (2013) 0.85
Anticancer activity of methyl-substituted oxaliplatin analogs. Mol Pharmacol (2012) 0.84
Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies. ChemMedChem (2015) 0.78
Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. Br J Cancer (2017) 0.75
Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. Macromol Biosci (2016) 0.75
Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. Sci Rep (2017) 0.75
Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. J Biol Inorg Chem (2011) 0.75
New trends for metal complexes with anticancer activity. Curr Opin Chem Biol (2008) 2.06
Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res (2002) 1.86
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem (2006) 1.77
Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal (2008) 1.73
The proteasome and its role in the degradation of oxidized proteins. IUBMB Life (2008) 1.32
Cell death and autophagy: cytokines, drugs, and nutritional factors. Toxicology (2008) 1.31
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat (2006) 1.25
Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat (2008) 1.24
Ruthenium antimetastatic agents. Curr Top Med Chem (2004) 1.20
Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer (2000) 1.18
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol (2007) 1.15
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). J Pharmacol Exp Ther (2004) 1.11
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans (2006) 1.10
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol (2008) 1.09
A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP. Cancer Res (2009) 1.06
Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochem Pharmacol (2007) 1.03
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett (2005) 1.01
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom (2009) 1.01
Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One (2009) 0.99
Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans (2007) 0.99
Unusual DNA binding modes for metal anticancer complexes. Biochimie (2009) 0.95
Strategies to improve the efficacy of platinum compounds. Curr Med Chem (2009) 0.87
New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer (2008) 0.85
Direct visualization and quantification of the anticancer agent, cis-diamminedichloro-platinum(II), in human lung cancer cells using in-air microparticle-induced X-ray emission analysis. Cancer Sci (2008) 0.85
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol (2006) 0.85
Acquisition of cisplatin-resistance in malignant mesothelioma cells abrogates Na+,K+,2Cl(-)-cotransport activity and cisplatin-induced early membrane blebbing. Cell Physiol Biochem (2008) 0.83
Glutathione and the regulation of cell death. Adv Exp Med Biol (1999) 0.82
Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR. J Biol Inorg Chem (2009) 0.81
Characterisation of zinc-binding domains of peroxisomal RING finger proteins using size exclusion chromatography/inductively coupled plasma-mass spectrometry. Biol Chem (2007) 0.81
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem (2005) 2.24
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. J Thorac Oncol (2015) 2.17
Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res (2003) 1.83
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J Inorg Biochem (2006) 1.77
DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet (2011) 1.65
Antitumour metal compounds: more than theme and variations. Dalton Trans (2007) 1.64
Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate (2002) 1.56
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev (2006) 1.55
Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res (2007) 1.52
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J Med Chem (2009) 1.51
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40
The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. Oncogene (2002) 1.37
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat (2007) 1.35
Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities. FASEB J (2005) 1.35
Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem (2009) 1.32
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers (2008) 1.27
Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. Inorg Chem (2003) 1.25
Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun (2009) 1.25
Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat (2008) 1.24
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther (2008) 1.23
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med (2009) 1.21
Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J Med Chem (2007) 1.19
Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol (2005) 1.18
Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem (2005) 1.18
The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. J Cell Sci (2006) 1.12
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans (2006) 1.10
The activin axis in liver biology and disease. Mutat Res (2006) 1.10
Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J (2010) 1.10
Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol (2002) 1.10
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol (2009) 1.09
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. J Med Chem (2007) 1.09
Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J Med Chem (2007) 1.08
Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem (2009) 1.08
Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia (2005) 1.08
Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia (2009) 1.07
Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol (2013) 1.07
FGF18 in colorectal tumour cells: autocrine and paracrine effects. Carcinogenesis (2007) 1.06
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat (2010) 1.05
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. J Inorg Biochem (2010) 1.04
Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control (2009) 1.04
Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. Inorg Chem (2011) 1.04
Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology (2011) 1.04
Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res (2012) 1.03
Accurate LC-ESI-MS/MS quantification of 2'-deoxymugineic acid in soil and root related samples employing porous graphitic carbon as stationary phase and a ¹³C₄-labeled internal standard. Electrophoresis (2014) 1.03
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. J Biol Inorg Chem (2010) 1.03
Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med Chem (2007) 1.03
Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochem Pharmacol (2007) 1.03
The first metal-based paullone derivative with high antiproliferative activity in vitro. Inorg Chem (2006) 1.02
Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem Pharmacol (2005) 1.01
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett (2005) 1.01
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom (2009) 1.01
A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther (2011) 1.01
Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J Inorg Biochem (2007) 1.01
Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans (2009) 1.00
A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.00
Gallium in cancer treatment. Curr Top Med Chem (2004) 0.98
Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol (2006) 0.98
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem (2005) 0.97
Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone. J Inorg Biochem (2002) 0.97
Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. Eur J Med Chem (2011) 0.96
Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol (2004) 0.96
European Commission's proposal for a council recommendation on cancer screening. BMJ (2003) 0.96
Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol (2009) 0.95
Carbohydrate-metal complexes and their potential as anticancer agents. Curr Med Chem (2008) 0.95
Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. J Med Chem (2011) 0.95
Promyelocytic HL60 cells express NADPH oxidase and are excellent targets in a rapid spectrophotometric microplate assay for extracellular superoxide. Toxicol Sci (2003) 0.95
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget (2012) 0.94
Relevance of peat-draining rivers for the riverine input of dissolved iron into the ocean. Sci Total Environ (2010) 0.93
Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol (2010) 0.93
Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. Nucl Med Biol (2008) 0.93
Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties. Inorg Chem (2007) 0.93
Targeted proteolysis of plectin isoform 1a accounts for hemidesmosome dysfunction in mice mimicking the dominant skin blistering disease EBS-Ogna. PLoS Genet (2011) 0.93
The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro. Inorg Chem (2007) 0.93
Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis (2002) 0.93
Self-reported prostate cancer screening in Austria. J Med Screen (2006) 0.93
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther (2013) 0.92